165 related articles for article (PubMed ID: 24472365)
21. Membranoproliferative glomerulonephritis and light-chain nephropathy in association with chronic lymphocytic leukemia.
Mutluay R; Aki SZ; Erten Y; Konca C; Yagci M; Barit G; Sindel S
Clin Nephrol; 2008 Dec; 70(6):527-31. PubMed ID: 19049712
[TBL] [Abstract][Full Text] [Related]
22. The role of complement in C3 glomerulopathy.
Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up.
Figuères ML; Frémeaux-Bacchi V; Rabant M; Galmiche L; Marinozzi MC; Grünfeld JP; Noël LH; Servais A
Hum Pathol; 2014 Nov; 45(11):2326-33. PubMed ID: 25260719
[TBL] [Abstract][Full Text] [Related]
24. A case of dense deposit disease associated with a group A streptococcal infection without the involvement of C3NeF or complement factor H deficiency.
Suga K; Kondo S; Matsuura S; Kinoshita Y; Kitano E; Hatanaka M; Kitamura H; Hidaka Y; Oda T; Kagami S
Pediatr Nephrol; 2010 Aug; 25(8):1547-50. PubMed ID: 20221776
[TBL] [Abstract][Full Text] [Related]
25. A CHILD WITH DENSE DEPOSIT DISEASE AND DECREASED CLASSIC COMPLEMENT PATHWAY ACTIVITY.
Trutin I; Oletić L; Galešić Ljubanović D; Turudić D; Milošević D
Acta Clin Croat; 2021 Mar; 60(1):141-145. PubMed ID: 34588735
[TBL] [Abstract][Full Text] [Related]
26. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
27. C3 nephritic factor associated with C3 glomerulopathy in children.
Nicolas C; Vuiblet V; Baudouin V; Macher MA; Vrillon I; Biebuyck-Gouge N; Dehennault M; Gié S; Morin D; Nivet H; Nobili F; Ulinski T; Ranchin B; Marinozzi MC; Ngo S; Frémeaux-Bacchi V; Pietrement C
Pediatr Nephrol; 2014 Jan; 29(1):85-94. PubMed ID: 24068526
[TBL] [Abstract][Full Text] [Related]
28. [Rapidly progressive proliferative glomerulonephritis with monoclonal immunoglobulin G deposits despite the mild histological changes. Case report].
Bajcsi D; Constantinou K; Krenács L; Barabás Z; Molnár S; Nyiraty S; Ábrahám G; Iványi B
Orv Hetil; 2018 Sep; 159(38):1567-1572. PubMed ID: 30227733
[TBL] [Abstract][Full Text] [Related]
29. Toward a working definition of C3 glomerulopathy by immunofluorescence.
Hou J; Markowitz GS; Bomback AS; Appel GB; Herlitz LC; Barry Stokes M; D'Agati VD
Kidney Int; 2014 Feb; 85(2):450-6. PubMed ID: 24067430
[TBL] [Abstract][Full Text] [Related]
30. C3 concentrations can be normal in patients with C3 glomerulopathy secondary to C3 nephritic factor.
Anderson H; Van Voorthuizen M; O'Donnell J; Beck S
J Clin Pathol; 2024 Jun; 77(7):503-506. PubMed ID: 38538072
[TBL] [Abstract][Full Text] [Related]
31. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
32. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.
Ravindran A; Fervenza FC; Smith RJH; De Vriese AS; Sethi S
Mayo Clin Proc; 2018 Aug; 93(8):991-1008. PubMed ID: 30077216
[TBL] [Abstract][Full Text] [Related]
33. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft.
Sawada A; Kawanishi K; Horita S; Koike J; Honda K; Ochi A; Komoda M; Tanaka Y; Unagami K; Okumi M; Shimizu T; Ishida H; Tanabe K; Nagashima Y; Nitta K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():48-52. PubMed ID: 26971743
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC
Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144
[TBL] [Abstract][Full Text] [Related]
35. C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition.
Sethi S; Quint PS; O'Seaghdha CM; Fervenza FC; Bijol V; Dorman A; Dasari S; Smith RJ; Kurtin PJ; Rennke HG
Am J Kidney Dis; 2016 Jun; 67(6):949-53. PubMed ID: 26896898
[TBL] [Abstract][Full Text] [Related]
36. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?
Alexander MP; Fervenza FC; De Vriese AS; Smith RJH; Nasr SH; Cornell LD; Herrera Hernandez LP; Zhang Y; Sethi S
J Nephrol; 2016 Apr; 29(2):203-209. PubMed ID: 26187133
[TBL] [Abstract][Full Text] [Related]
37. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Schena FP; Esposito P; Rossini M
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947692
[TBL] [Abstract][Full Text] [Related]
38. C3 glomerulopathy: what's in a name?
D'Agati VD; Bomback AS
Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
[TBL] [Abstract][Full Text] [Related]
39. Type of immune and complement deposits and response of immunosuppressive treatment on Membranoproliferative Glomerulonephritis -- a single centre experience.
Imtiaz S; Dhrolia MF; Nasir K; Salman B; Ahmad A
J Pak Med Assoc; 2015 Sep; 65(9):995-1000. PubMed ID: 26338748
[TBL] [Abstract][Full Text] [Related]
40. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL
Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
